Plataforma BIOBADASER III

Registro Español de Acontecimientos Adversos de Terapias Dirigidas en Enfermedades Reumáticas

Biobadaser Fase III

Subtype-specific cancer risk with JAK inhibitors and biologic DMARDs in rheumatoid arthritis: comparative analysis within the JAK-pot collaboration 1534 real-world patients with axial spondyloarthritis

15/09/2026

Ciribe B et al. (JAK-pot)

https://scientific.sparx-ip.net/archiveeular/?view=1&c=a&searchfor=jak-pot&item=2026OP086
 

EULAR 2026